Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study.
Roberto De IccoGiuseppe FiamingoRosaria GrecoSara BottiroliChiara DemartiniAnna Maria ZanaboniMarta AllenaElena GuaschinoDaniele MartinelliAlessia PutortìValentina GrilloGrazia SancesCristina TassorelliPublished in: Cephalalgia : an international journal of headache (2020)
Different migraine phenotypes, characterized by different treatment susceptibility, may exist as suggested by the divergent behavior between neurophysiological and biomolecular findings in 30% Responder vs. NON-responder patients.The study protocol was registered at clinicaltrials.gov (NCT04361721).